New chief scientific officer Tony Wood has said he is determined that GSK will take “smart risks” wherever opportunities present themselves – but has hinted that it will be “pragmatic” about expanding its presence in oncology.
GSK To Take ‘Smart Risks’ Across Portfolio – But Will Be ‘Pragmatic’ About Oncology Expansion
US FDA Sets May 2023 Decision Date For RSV Vaccine
GSK’s new R&D leader, Tony Wood, has promised a more hard-nosed attitude to picking winners – including a ‘pragmatic’ approach to the hyper-competitive field of oncology.
More from Business
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
More from Scrip
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.